drugset / Trial / NCT01529957

A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion

NCT01529957

Phase 1 Completed 176 enrolled TaiGen Biotechnology Co., Ltd.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in healthy Chinese volunteers.

Timeline

Start
2008-09
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nemonoxacin Small molecule 25 mg Intravenous
Comparator Nemonoxacin Small molecule 50 mg Intravenous
Comparator Nemonoxacin Small molecule 125 mg Intravenous
Comparator Nemonoxacin Small molecule 250 mg Intravenous
Comparator Nemonoxacin Small molecule 500 mg Intravenous
Comparator Nemonoxacin Small molecule 650 mg Intravenous
Comparator Nemonoxacin Small molecule 750 mg Intravenous
Comparator Nemonoxacin Small molecule 1000 mg Intravenous
Comparator Nemonoxacin Small molecule 1250 mg Intravenous

Indications

No indication recorded.